The U.S. Food and Drug Administration (FDA) has approved ischemia-modified albumin (IMA) as a serum biomarker for cardiac ischemia, which is used in the risk assessment of patients suspected of having acute coronary syndrome [2]. This evidence concerns the gene ALB and acute coronary syndrome.